These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 37222860)
1. Commentary: Consensus Guidelines on the Appropriate Use of Brand-Name and Generic Anti-Seizure Medication for the Management of Epilepsy in the Gulf Region. Alsaadi T; Almadani A; Al-Hashel J; Al Salti A; Melikyan G; Khan RA Neurol Ther; 2023 Aug; 12(4):1015-1031. PubMed ID: 37222860 [TBL] [Abstract][Full Text] [Related]
2. Pricing dynamics of anti-seizure medications in the U.S. Javarayee P; Mtchedlidze T; Snell W; Mahesha V; Meylor J; Shahrukh S; Pollock S; Sah J; Dong Y; Patel H Seizure; 2024 Nov; 122():26-33. PubMed ID: 39306895 [TBL] [Abstract][Full Text] [Related]
4. Changes in the Use of Brand Name and Generic Medications and Total Prescription Cost Among Medicare Beneficiaries With Epilepsy. Terman SW; Lin CC; Kerr WT; DeLott LB; Callaghan BC; Burke JF Neurology; 2022 Aug; 99(8):e751-e761. PubMed ID: 35705496 [TBL] [Abstract][Full Text] [Related]
5. Recommendations for treatment strategies in people with epilepsy during times of shortage of antiseizure medications. Asadi-Pooya AA; Patel AA; Trinka E; Mazurkiewicz-Beldzinska M; Cross JH; Welty TE Epileptic Disord; 2022 Oct; 24(5):751-764. PubMed ID: 35894673 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic monitoring of anti-seizure medications in low- and middle-income countries: a systematic review. Odhiambo M; Kariuki SM; Newton CR Wellcome Open Res; 2021; 6():92. PubMed ID: 37457427 [TBL] [Abstract][Full Text] [Related]
7. Dose Adjustment of Concomitant Antiseizure Medications During Cenobamate Treatment: Expert Opinion Consensus Recommendations. Smith MC; Klein P; Krauss GL; Rashid S; Seiden LG; Stern JM; Rosenfeld WE Neurol Ther; 2022 Dec; 11(4):1705-1720. PubMed ID: 36057761 [TBL] [Abstract][Full Text] [Related]
8. Patterns of anti-seizure medication (ASM) use in pediatric patients with surgically managed epilepsy: A retrospective review of data from Boston Children's Hospital. Wang S; Rotenberg A; Bolton J Epilepsy Res; 2020 Feb; 160():106257. PubMed ID: 32004867 [TBL] [Abstract][Full Text] [Related]
9. Evolution of antiseizure medication use and cost in the United States of America 2006-2021. Sánchez Fernández I; Gaínza-Lein M; Amengual-Gual M; Barcia Aguilar C; Romeu A; Torres A; Jonas R; Douglass LM Seizure; 2023 Nov; 112():128-138. PubMed ID: 37832279 [TBL] [Abstract][Full Text] [Related]
10. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard. Ting TY; Jiang W; Lionberger R; Wong J; Jones JW; Kane MA; Krumholz A; Temple R; Polli JE Epilepsia; 2015 Sep; 56(9):1415-24. PubMed ID: 26201987 [TBL] [Abstract][Full Text] [Related]
11. Treatment of seizures in the neonate: Guidelines and consensus-based recommendations-Special report from the ILAE Task Force on Neonatal Seizures. Pressler RM; Abend NS; Auvin S; Boylan G; Brigo F; Cilio MR; De Vries LS; Elia M; Espeche A; Hahn CD; Inder T; Jette N; Kakooza-Mwesige A; Mader S; Mizrahi EM; Moshé SL; Nagarajan L; Noyman I; Nunes ML; Samia P; Shany E; Shellhaas RA; Subota A; Triki CC; Tsuchida T; Vinayan KP; Wilmshurst JM; Yozawitz EG; Hartmann H Epilepsia; 2023 Oct; 64(10):2550-2570. PubMed ID: 37655702 [TBL] [Abstract][Full Text] [Related]
12. An economic evaluation of vagus nerve stimulation as an adjunctive treatment to anti-seizure medications for the treatment of drug-resistant epilepsy in England. Raspin C; Shankar R; Barion F; Pollit V; Murphy J; Sawyer L; Danielson V J Med Econ; 2021; 24(1):1037-1051. PubMed ID: 34348576 [TBL] [Abstract][Full Text] [Related]
13. An economic evaluation of vagus nerve stimulation as an adjunctive treatment to anti-seizure medications for the treatment of drug resistant epilepsy in the United States. Raspin C; Faught E; Armand J; Barion F; Pollit V; Murphy J; Danielson V J Med Econ; 2023; 26(1):189-199. PubMed ID: 36691763 [TBL] [Abstract][Full Text] [Related]
14. Safety of brand name to generic substitution of lacosamide in patients with epilepsy - A prospective single-center observational study. Bosak M; Woźniak M; Kasprzycki M; Słowik A Seizure; 2023 Oct; 111():203-205. PubMed ID: 37683453 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of switching from brand-name to domestic generic levetiracetam in children with epilepsy. Liang MJ; Qiu WF; Zhang JW; Li XP; Shi GA; Zhai QX; Zhang YX; Chen ZH Zhongguo Dang Dai Er Ke Za Zhi; 2022 Mar; 24(3):285-289. PubMed ID: 35351259 [TBL] [Abstract][Full Text] [Related]
16. Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs. Perucca E; Albani F; Capovilla G; Bernardina BD; Michelucci R; Zaccara G Epilepsia; 2006; 47 Suppl 5():16-20. PubMed ID: 17239100 [TBL] [Abstract][Full Text] [Related]
17. Shortages of antiseizure medications in Australia and the association with patient switching, and adherence in a community setting. Welton J; Stratton G; Schoeninger B; Low MH; Moody A; D'Souza W Epilepsy Behav; 2023 Apr; 141():109145. PubMed ID: 36913876 [TBL] [Abstract][Full Text] [Related]
18. Brand name to generic substitution of levetiracetam in patients with epilepsy. Gha-Hyun L; Dae SJ Seizure; 2018 Aug; 60():127-131. PubMed ID: 29960217 [TBL] [Abstract][Full Text] [Related]
19. Is bioavailability altered in generic versus brand anticonvulsants? Jankovic SM; Ignjatovic Ristic D Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):329-32. PubMed ID: 25440299 [TBL] [Abstract][Full Text] [Related]
20. Safety of switching from brand-name to generic levetiracetam in patients with epilepsy. Bosak M; Słowik A; Turaj W Drug Des Devel Ther; 2017; 11():2287-2291. PubMed ID: 28814836 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]